Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Daniel C. Montano has announced that he has won a $1 million dollar judgement against CVBT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano announces that he wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT, within the next 30 days the shareholders will know that CVBT/VT has no financial viability and is an empty shell of a company.
I fear that Dan Montano will seize all of the assets, including IP, that CVBT has and will sue the CVBT/VT directors for their actions.
DEBTORS EXAM FOR CARDIOVASCULAR BIOTHERAPEUTICS (CVBT)/VENTURIS THERAPEUTICS
Rumor has it that as a result of Dan Montano's court victory, which has given him a judgment of a $1 million dollar claim against Venturis Therapeutics, confirmed by the Federal Court, that Dan Montano will be seeking a debtors exam for CVBT in the month of May. I am worried that this debtors exam will reveal the true financial position of CVBT/Venturis Therapeutics and make the CVBT directors liable.
How will this debtor's exam affect the future of CVBT? Will there be a future for CVBT following this major legal victory for Daniel C. Montano? Where will CVBT get the $1 million dollars to pay Mr. Dan Montano?
THE UNITED STATES FEDERAL COURT HAS CONFIRMED DAN MONTANO'S ONE MILLION DOLLAR CLAIM AGAINST CVBT/VENTURIS THERAPEUTICS
Furthermore, with Zhittya Genesis Medicine and Mrs. Montano being ENTIRELY DISMISSED from the lawsuits that Venturis brought fourth there is a clear path for Mr. Daniel Montano to forcibly collect on his 1 million dollar claim. Venturis is at the hands of Dan Montano! Why were we not made aware of this? Why is our administration so quick to announce when lawsuits are filed but not when we are miserably defeated and punished for our defeat?
I worry that Mr. Montano will wipe Venturis off the face of the map with his new ability to forcibly collect on his one million dollar award which has been confirmed by the United States Federal Court.
Daniel C. Montano wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021.
Dan Montano's Clear Victory over CVBT
CardioVascular BioTherapeutics/Venturis Therapeutics has lost yet another court battle to Dan Montano. As a result of this miserable defeat, the US Federal Court has confirmed Dan Montano's $1 million dollar judgment against CVBT/Venturis Therapeutics despite bringing on the case themselves!
Despite what individuals say on this page, there is no right of offset to this matter! Dan Montano's $1 million dollar judgement has no offset. The Court Records clearly indicate the Dan Montano's $1 million dollar judgement. Those same Court Records DO NOT INDICATE THAT VENTURIS THERAPEUTICS IS OWED ANYTHING FROM DAN MONTANO. There is no right of offset. We can only hope that Dan Montano will not initiate a debtor's exam.
I think Venturis should start raising money at retirement homes. That seems to be working for Dan Montano and Shittya. Then Venturis would have the money to pay Dan who in turn could chip away at that millions he owes Venturis.
Or maybe they can get a sweet RMOnopoly investment. Dan clearly accepts RMOnopoly money.
CVBT/VT LAWYERS ADMIT CVBT/VT IS WORTHLESS IN FEDERAL COURT
The truth about Cardiovascular Biotherapeutics/Venturis Therapeutics is coming out as a result of the lawsuit they have filed against our former administration.
Our own lawyers were forced to withdraw themselves from the case as a result of Cardiovascular Biotherapeutics'/Venturis Therapeutics' inability to pay the company's lawyers.
As bad as that may sound, this is not all, the company's lawyer then went on to state: Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.
Our own lawyers admitted in Federal District Court the incompetence of our administration. We are a worthless company. The United States Federal Court states it in their records, our own lawyers state it, our former administrative members say it.
Cardiovascular Biotherapeutics/Venturis Therapeutics is officially worthless.
"it has become evident that there are currently no assets or revenue streams from which payments can be made."
It gets worse. Not only did our company's lawyers withdraw themselves from Cardiovascular Biotherapeutics/Venturis Therapeutics' lawsuit in federal court, they have also emphasized how defunct Venturis Therapeutics/CVBT truly is in a statement to the United States Federal Court. I have posted another excerpt:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 23-25 read as follows:
"Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."
"...unpaid fees in excess of $200,000..."
I was able to get my hands on some court documents and was able to find more about why CVBT/VT's lawyers have withdrawn themselves from their suit in Federal District Court. It appears that we did not have enough money to pay them. I have posted an excerpt here:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 15-17 are as follows:
Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.
"Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement."
I have managed to obtain some court documents further ellaborating why our company's lawyer has withdrawn himself from the case. I have posted an excerpt here:
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC.,
formerly known as CARDIOVASCULAR
BIOTHERAPEUTICS, INC.
Claimant,
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN
THE ALTERNATIVE, MOTION TO
WITHDRAW AS COUNSEL FOR
VENTURIS THERAPEUTICS, INC.
Page 3, Line 16 Reads as follows:
However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.
$1,100,000 awarded to Daniel C. Montano by the US Federal Court against CVBT/VT
The United States Federal court has confirmed Daniel C. Montano's $1.1 million dollar judgement against CVBT/VT as a result of their fraudulent and frivolous lawsuit claiming that Daniel C. Montano's IP was not his.
The US Federal Court not only confirmed that Daniel C. Montano has a $1 million dollar (non-off-settable) judgement against CVBT/VT, but that Daniel C. Montano and Zhittya Genesis Medicine own all of their IP.
Daniel C. Montano announces that the US Federal Court has confirmed his IP
The United States Federal Court has confirmed the ruling in favor of Daniel C. Montano citing that Dan Montano owns all of the IP that he and his company, Zhittya Genesis Medicine are developing.
The United States Federal Court's confirmation comes as a result of Cardiovascular Biotherapeutics/ Venturis Therapeutics' own management team testifying in favor of Daniel C. Montano, stating that the IP that Dan Montano and Zhittya Genesis Medicine have been developing are 100% theirs.
Daniel C. Montano Announces His Victory over CVBT/VT
Despite years of fraudulent and frivolous lawsuits it appears that Daniel C. Montano is now victorious over the crooks that run Cardiovascular Biotherapeutics/Venturis Therapeutics.
Daniel C. Montano has been awarded an over $1 million dollar judgment against CVBT/VT as a result of the frivolous lawsuit that they had originally filed.
Daniel C. Montano's more than $1,000,000 dollar judgement against Cardiovascular BioTherapeutics/Venturis Therapeutics has been confirmed by the United States Federal Court System.
Dan Montano's clear victory over CVBT/VT could result in a forced debtors exam against CVBT/VT in order for Montano to collect on his judgement.
Daniel C. Montano has announced that he has won a $1 million dollar judgement against CVBT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano announces that he wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT, within the next 30 days the shareholders will know that CVBT/VT has no financial viability and is an empty shell of a company.
I fear that Dan Montano will seize all of the assets, including IP, that CVBT has and will sue the CVBT/VT directors for their actions.
DEBTORS EXAM FOR CARDIOVASCULAR BIOTHERAPEUTICS (CVBT)/VENTURIS THERAPEUTICS
Rumor has it that as a result of Dan Montano's court victory, which has given him a judgment of a $1 million dollar claim against Venturis Therapeutics, confirmed by the Federal Court, that Dan Montano will be seeking a debtors exam for CVBT in the month of May. I am worried that this debtors exam will reveal the true financial position of CVBT/Venturis Therapeutics and make the CVBT directors liable.
How will this debtor's exam affect the future of CVBT? Will there be a future for CVBT following this major legal victory for Daniel C. Montano? Where will CVBT get the $1 million dollars to pay Mr. Dan Montano?
THE UNITED STATES FEDERAL COURT HAS CONFIRMED DAN MONTANO'S ONE MILLION DOLLAR CLAIM AGAINST CVBT/VENTURIS THERAPEUTICS
Furthermore, with Zhittya Genesis Medicine and Mrs. Montano being ENTIRELY DISMISSED from the lawsuits that Venturis brought fourth there is a clear path for Mr. Daniel Montano to forcibly collect on his 1 million dollar claim. Venturis is at the hands of Dan Montano! Why were we not made aware of this? Why is our administration so quick to announce when lawsuits are filed but not when we are miserably defeated and punished for our defeat?
I worry that Mr. Montano will wipe Venturis off the face of the map with his new ability to forcibly collect on his one million dollar award which has been confirmed by the United States Federal Court.
Daniel C. Montano wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021.
Dan Montano's Clear Victory over CVBT
CardioVascular BioTherapeutics/Venturis Therapeutics has lost yet another court battle to Dan Montano. As a result of this miserable defeat, the US Federal Court has confirmed Dan Montano's $1 million dollar judgment against CVBT/Venturis Therapeutics despite bringing on the case themselves!
Despite what individuals say on this page, there is no right of offset to this matter! Dan Montano's $1 million dollar judgement has no offset. The Court Records clearly indicate the Dan Montano's $1 million dollar judgement. Those same Court Records DO NOT INDICATE THAT VENTURIS THERAPEUTICS IS OWED ANYTHING FROM DAN MONTANO. There is no right of offset. We can only hope that Dan Montano will not initiate a debtor's exam.
Yes, that is a really great idea. If all VT shareholders supported Dan then he would have a few quid to be able to settle his many debts. Maybe that would restore his faith in humankind.
Does Zhittya have any patents, assets or revenue streams?? Does anyone know - if you do, please share with us all. And if Zhittya does, then fabulous news because they can use the registered patents or assets to raise funds to endeavour to progress their science. And that would be a really good thing for humankind as well.
I am sure there are noticeable and distinct differences in the Zhittya patents and science v the CVBT patents and science. That is good, because we really would not want further litigation on the merits or otherwise of copycat science. All shareholders in CVBT and Zhittya have surely had enough of that by now. I know I have.
It is good that Zhittta has been progressing its science in Mexico since that is a different market, different type of patient and different health regulator as compared to what CVBT is looking to do in the US. Yes, very good that Dan had the common sense to pursue his science (even though it is remarkably similar to CVBT science) in a different country. Let us keep potential litigation to an absolute minimum I say !!
I must admit, I have never felt more confident that Dan’s science in Mexico and Calvin’s science in USA is getting on track. Finally both will be able to do good things for mankind. And in these latter stages Covid pandemic, I will happily take all good news possible.
So thank you both. I hope you have a fair wind and you make great progress and headway. And also that the biotech regulators support both scientific endeavours fully. God speed !!
Now Montano only owes Venturis 1.4 Million. Please buy his IPO so Venturis can get paid.
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Debtors Exam for CVBT
Zhittya Genesis Medicine Inc., (formerly known as Zhittya Regenerative Medicine), competitor to Cardiovascular Biotherapeutics Inc., has announced its CEO, Daniel C. Montano, has been awarded an over $1 million legal judgement, confirmed by the US Federal Court, against CVBT and its new name, Venturis Therapeutics.
Mr. Dan Montano is now pursuing the involuntary collections of his judgements against CVBT.
Zhittya Genesis Medicine also announced that ALL legal allegations made against Zhittya Genesis Medicine have been DISMISSED by the judge.
After seven years of lawsuits by CVBT against Zhittya it is clear that CVBT has come out as the ultimate loser after this judgement against them for $1 million. In all this time, CVBT has FAILED TO CONDUCT CLINICAL TRIALS, MANUFACTURE THE DRUG, OR PAID ANY PART OF ITS $30 MILLION IN DELINQUENT BILLS.
Daniel C. Montano wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021.
$1,100,000 awarded to Daniel C. Montano by the US Federal Court against CVBT/VT
The United States Federal court has confirmed Daniel C. Montano's $1.1 million dollar judgement against CVBT/VT as a result of their fraudulent and frivolous lawsuit claiming that Daniel C. Montano's IP was not his.
The US Federal Court not only confirmed that Daniel C. Montano has a $1 million dollar (non-off-settable) judgement against CVBT/VT, but that Daniel C. Montano and Zhittya Genesis Medicine own all of their IP.
Daniel C. Montano announces that the US Federal Court has confirmed his IP
The United States Federal Court has confirmed the ruling in favor of Daniel C. Montano citing that Dan Montano owns all of the IP that he and his company, Zhittya Genesis Medicine are developing.
The United States Federal Court's confirmation comes as a result of Cardiovascular Biotherapeutics/ Venturis Therapeutics' own management team testifying in favor of Daniel C. Montano, stating that the IP that Dan Montano and Zhittya Genesis Medicine have been developing are 100% theirs.
Daniel C. Montano Announces His Victory over CVBT/VT
Despite years of fraudulent and frivolous lawsuits it appears that Daniel C. Montano is now victorious over the crooks that run Cardiovascular Biotherapeutics/Venturis Therapeutics.
Daniel C. Montano has been awarded an over $1 million dollar judgment against CVBT/VT as a result of the frivolous lawsuit that they had originally filed.
Daniel C. Montano's more than $1,000,000 dollar judgement against Cardiovascular BioTherapeutics/Venturis Therapeutics has been confirmed by the United States Federal Court System.
Dan Montano's clear victory over CVBT/VT could result in a forced debtors exam against CVBT/VT in order for Montano to collect on his judgement.
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
CVBT/VT LAWYERS ADMIT CVBT/VT IS WORTHLESS IN FEDERAL COURT
The truth about Cardiovascular Biotherapeutics/Venturis Therapeutics is coming out as a result of the lawsuit they have filed against our former administration.
Our own lawyers were forced to withdraw themselves from the case as a result of Cardiovascular Biotherapeutics'/Venturis Therapeutics' inability to pay the company's lawyers.
As bad as that may sound, this is not all, the company's lawyer then went on to state: Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.
Our own lawyers admitted in Federal District Court the incompetence of our administration. We are a worthless company. The United States Federal Court states it in their records, our own lawyers state it, our former administrative members say it.
Cardiovascular Biotherapeutics/Venturis Therapeutics is officially worthless.
"it has become evident that there are currently no assets or revenue streams from which payments can be made."
It gets worse. Not only did our company's lawyers withdraw themselves from Cardiovascular Biotherapeutics/Venturis Therapeutics' lawsuit in federal court, they have also emphasized how defunct Venturis Therapeutics/CVBT truly is in a statement to the United States Federal Court. I have posted another excerpt:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 23-25 read as follows:
"Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."
"...unpaid fees in excess of $200,000..."
I was able to get my hands on some court documents and was able to find more about why CVBT/VT's lawyers have withdrawn themselves from their suit in Federal District Court. It appears that we did not have enough money to pay them. I have posted an excerpt here:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 15-17 are as follows:
Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.
"Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement."
I have managed to obtain some court documents further ellaborating why our company's lawyer has withdrawn himself from the case. I have posted an excerpt here:
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC.,
formerly known as CARDIOVASCULAR
BIOTHERAPEUTICS, INC.
Claimant,
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN
THE ALTERNATIVE, MOTION TO
WITHDRAW AS COUNSEL FOR
VENTURIS THERAPEUTICS, INC.
Page 3, Line 16 Reads as follows:
However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.
I hear on the bush telegraph that VT has begun the collection process to get hold of the $1,700,000 that Dan Montano owes the company. I think we'll hear next week how that is progressing. Fingers crossed!!
I have the version 18 of the VT presentation which looks great. Does anyone have a newer copy at hand?
I am trying to work out how many patents VT now has.
Ok I get it, two men went the battle and we had a winner and a looser, and they were bitter till the end.
The current reality is, we have the victor controlling a company with questionable finances who haven’t held a AGM for ages and still hasn’t released a yearly review of the company(its June!!) or any given communication to shareholder and doesn’t disseminate any audited financials.
Who is going to answer the all important questions of today?
Are the legal wrangles over?
Is the company liquid?
When will we have an AGM?
Can we see audited financials?
Why won’t management communicate to shareholders?
The reality is no shareholder fundamentally cares about what happened in 2012.
Until someone can answer these basic question, a history lesson of 2012 is irrelevant in my mind.
It’s not amazing is it.
Facts only, with evidence please.
Thanks
Twd - life is a journey so let us first fact check how CVBT got to where it is today. Then we have the background information to calmly and openly discuss where it may hopefully go in the future.
What the Court documents indicate it there has been a whole heap of litigation between the Montano faction and the Wallen faction. The early litigation was brought by Wallen faction to remove Montano faction from the running of the company. In successfully doing that, Montano lost control of his 30-odd million shares, had to file for personal bankruptcy, and had a Court ruling he was liable for personal guarantees extended by him to Wallen amounting to approx $2m.
To Montano’s credit, he was trying to make CVBT work by giving his personal guarantees to corporate borrowings of CVBT back in the day. But sadly he didn’t manage to deliver on strategy and financing back then. Having lost his shares in CVBT, he was then no longer required to act in the best interests of shareholders since he no longer was CEO of the company.
There is a plethora of Court documents narrating the efforts of Wallen to keep the ‘lights on’ at the company and the attempts by Montano setting up in opposition to the company. That has all finally been ruled on by various judges and also an Arbitration forum. The outcome is Montano was awarded some $900k award for back wages earned but unpaid for his efforts when still employed as CEO back in 2012 and 2013 mainly.
Do we need the detail of how we get to that - not really. But anyone that is interested in that can ask here and I will post what I can from the Court extracts.
Hopefully if the detail behind the litigation events of the past near 10 years is brought out into the open, those shareholders and others interested in discussing the future potential of this company will be able to do that rather than any conversation being quickly drowned out by references to the company history. That is all in the past - shall we try and look forward to seeing if the Wallen faction can now deliver what the Montano faction sadly didn’t manage to.
Grant Gordon and other administration members are simply trying to distract the shareholders that Cardiovascular Biotherapeutics/Venturis Therapeutics has zero value whatsoever. As the lawyer said so clearly in US Federal Court records: CVBT/VT has no assets and no revenue stream.
We are, as the young folks like to say, broke.
Helpful thanks, but how does this help us with regards to knowing whether VT has liquidity issues now and run out of cash today?
The only question we need answered is do they still have liquidity as of this month and moving forward?
Is Calvin going to lend the business money again, because defaulting on a 200k legal bill doesn’t look great.
The Proxy Fight for Control of CVBT.
https://www.docketbird.com/court-documents/Cardiovascular-Biotherapeutics-Inc/Amended-Motion-for-Summary-Judgment-with-alternative-relief-with-Certificate-of-Service-Filed-by-FRANKLIN-L-BROYLES-on-behalf-of-CARDIOVASCULAR-BIOTHERAPEUTICS-INC-related-document-s-68-Motion-for-Summary-Judgment-filed-by-Alleged-Debtor-CARDIOVASCUL/nvb-2:2018-bk-15410-00080
A short extract below is copied from the above link/ Court record. Stick with me - there are 2 sides to the entire story.
Prior to 2012 Calvin A. Wallen, III was a major lender to and investor in CVBT. Wallen became concerned that CVBT was being mismanaged and initiated a proxy fight for control of CVBT, the alleged debtor. CVBT is a corporation chartered in Delaware. In 2013 a Delaware court adjudicated the Wallen proxy fight for control of CVBT. There were two factions: the Daniel C. 20 Montano ("Montano") faction and the Calvin A. Wallen, III ("Wallen) faction. The Wallen faction prevailed and the Montano faction was totally removed from management by the Delaware Court. Genuine copies of the two orders entered by the Delaware Court are attached as Exhibits 1 and 2 to the Motion and the Affidavit of Wallen. (Case 18-15410-gs Doc 80 Entered 12/11/18 19:54:58 Page 3 of 17 1 B.) The Chapter 7 Bankruptcy of Daniel C. Montano. At the time that Montano was removed from CVBT as a manager Montano had personally guaranteed over $2,000,000 of debt owed by CVBT to Wallen. Wallen sued Montano under the guarantee and obtained a state court judgment for the debt. Wallen began collection actions, which caused Montano to file a voluntary Chapter 7 in this District.
Battle for control of CVBT 2014.
https://www.casemine.com/judgement/us/5914e616add7b0493490b6b7
The link will help inform readers of the skirmish for control of CVBT starting back in 2014. Whilst this Opinion did not allow Wallen to gain control of the CVBT Board, it put in place a stand-still agreement until a next motion was filed and confirmed which allowed shareholders to vote for the removal of then CEO Dan Montano and his family members, being replaced by Calvin Wallen and various biotech and finance professionals.
I will post links to subsequent litigation outcomes over the upcoming days. The intention here is to be factual about what has happened from Calvin Wallen gaining control of CVBT up to now, including the successful award of initially $900k plus costs to Dan Montano for back wages in 2012/13.
I believe this message board will be better served for all if factual information is posted. I believe Court transcripts can be taken as factual documentary evidence.
VENTURIS THERAPEUTICS/CVBT FRAUD?
Cardiovascular Biotherapeutics'/Venturis Therapeutics' lawyer made a statement on the US Federal Court records citing that our company was worthless. The lawyer stated: "Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."
This statement was made in April 12, 2021.
However, this did not stop Venturis Therapeutics from officially promoting the company. After their lawyer's statement, Venturis then went on to post to their official company website about newly secured patents, obviously in an attempt to raise money from such an announcement.
Their statement was made in April 30, 2021.
Clearly, Venturis Therapeutics' administration was attempting to bring value to the company despite clear statements on the US Federal Court records citing their lack of assets (including patents). Would this make Cardiovascular Biotherapeutics/Venturis Therapeutics liable for fraud? Would this make the company administrators liable for fraud?
That statement can be found here: Venturis/CVBT Statement April 30, 2021
Is Calvin Wallen III liable for fraud?
Is Robert Schleizer liable for fraud?
Is Elvia Gustavson liable for fraud?
Is Warren Sherman, MD liable for fraud?
Is David M. Ornitz, MD, PhD liable for fraud?
Is Arnold I. Chin, MD, PhD liable for fraud?
Is the Board of Directors such as Grant Gordon, John S. Ross, among others, liable for fraud?
I am still confused though. You mention what has been posted by others here - you are the main person posting about the terrible state of the company. And now the lawyers have confirmed your views - no assets and no income stream and laughable IP. So basically, as you have often said here, it will soon be time to turn the lights out.
There is an incredible amount of previous litigation over the years, which has cost me a small fortune to download from Pacer etc. The content is so rich that basically they should write a book or sell the movie rights. I am no lawyer myself but basically I believe where matters stand are as follows:
Montano has won an arbitration award of $900k less $50k set-off. Plus some costs. This is for back wages in the period when Montano and team were still trying to keep the lights on themselves and spending the lifeline funding provided by Wallen. Sadly they didn’t succeed in keeping the company afloat, and the loans and funding extended by Wallen, which were underpinned by Personal Guarantees issued by Montano to Wallen, were called in. Montano obviously couldn’t pay back and eventually, after an extended legal tussle, Wallen won control of the Board through a shareholder vote majority and the Montano faction was removed.
This particular story has played out countless times over the years. The detail of the extended litigation and arbitration is ‘a good read’ but ultimately things are what they are. And what are they?
Montano wants his back wages awarded by the arbitration award paid to him. And Wallen wants the money he provided to try keeping the company afloat when Montano was earning those ‘back wages’ repaid. In my mind, our next litigation instalment will be all about whether the Personal Guarantees provided by Montano were fair and reasonable given the then circumstances. No doubt Dan will challenge and Calvin will defend - but at some point in time, in order for Calvin to collect on the personal guarantees, Calvin will have to attack and Dan will need to do some defending of his own.
Others here are saying the personal guarantee amount due Wallen is $2.5m - I haven’t had time to look back through all the historical Court transcripts yet, but give me time.
Maybe the Arbitrator was a clever guy in awarding Dan such a high amount for ‘back wages’ of around 900k for a 2 year period. He acknowledges that Dan was at significant personal risk as a result of the personal guarantees he provided to Calvin at that time, and was therefore highly motivated to work hard for himself and the company in order to ensure the PGs were never exercised.
Ultimately though Dan again failed in these efforts which sadly for him is a recurring and consistent trend. But it does leave the onlooking shareholders with a potential ‘thrilling final chapter’ in this painfully long running saga.
CVBT/VT's lawyer stated that the company was worthless in late April of 2021. Posts like this, among others, seem to be promoting the stock in mid-May despite the fact that company administrators must have known of the lawyer's statement of fact. Since this post was made after administrators knew that the company had zero value, according to their lawyer and found in US Federal Court records, does that mean that administrators such as Grant Gordon have knowingly committed fraud? Are other administrators such as Mike Flaa and Calvin Wallen III also responsible for committing fraud by attempting to promote the stock knowing that the US Federal Court records state that the company had no value?
You would have to ask Dan Montano why he is doing what he is doing, I can't say. But based on what I've read here posted by others, I suspect the reason why Dan is pursuing the company's assets to liquidate them (even if they are worthless) is because he's required to do this first in order to then pursue the officers and directors personally and their insurance company if there is one to collect his judgment. I'm not a lawyer nor am I involved, but if I understand correctly, actions taken by the officers and directors throughout this extended ordeal have created personal liability that allows for the piercing of the corporate veil. But I believe that first Montano is required to collect what he can from the company before he goes after the individuals.
CVBT/VT LAWYERS ADMIT CVBT/VT IS WORTHLESS IN FEDERAL COURT
The truth about Cardiovascular Biotherapeutics/Venturis Therapeutics is coming out as a result of the lawsuit they have filed against our former administration.
Our own lawyers were forced to withdraw themselves from the case as a result of Cardiovascular Biotherapeutics'/Venturis Therapeutics' inability to pay the company's lawyers.
As bad as that may sound, this is not all, the company's lawyer then went on to state: Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.
Our own lawyers admitted in Federal District Court the incompetence of our administration. We are a worthless company. The United States Federal Court states it in their records, our own lawyers state it, our former administrative members say it.
Cardiovascular Biotherapeutics/Venturis Therapeutics is officially worthless.
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3648
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |